GSK3 beta study in patients with Myotonic Dystrophy 1
强直性肌营养不良患者的 GSK3 beta 研究 1
基本信息
- 批准号:10593112
- 负责人:
- 金额:$ 20.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-15 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:19q3&apos Untranslated RegionsAddressAdultAffectAntisense OligonucleotidesBiochemicalBiopsyBloodBlood specimenCDK4 geneCUG repeatChildhoodChromosomesClinical ResearchClinical TrialsComplexDevelopmentDiseaseFamilyFibroblastsGenesGoalsGrowthHumanInfantKnowledgeLeftLengthLinkMediatingMessenger RNAModificationMolecularMolecular AnalysisMonitorMulticenter StudiesMusMuscleMuscle CellsMuscle FibersMuscle functionMuscular AtrophyMyoblastsMyofibroblastMyopathyMyotoniaMyotonic DystrophyMyotonic dystrophy type 1Neuromuscular DiseasesNewborn InfantPathologicPathologyPathway interactionsPatientsPenetrancePhasePhase I/II Clinical TrialPhenotypePhosphotransferasesPilot ProjectsPublishingRNA ProcessingRNA SplicingRNA-Binding ProteinsSeveritiesSeverity of illnessSignal TransductionSkeletal MuscleSkinSolidTestingTherapeuticTimeTreatment outcomeanxiety reductionbiopharmaceutical industryclinical developmentcohortcyclin D3glycogen synthase kinase 3 betaimprovedin vivoinhibitormouse modelmutantnovel therapeutic interventionpostnatalpreventsmall moleculetherapeutic target
项目摘要
Myotonic Dystrophy type 1 (DM1) is a complex neuro-muscular disease, caused by an expansion of CTG
repeats in the 3’ UTR of DMPK gene on the chromosome 19q. The longest CTG expansions affect infants
causing congenital DM1 (CDM1). CTG repeats cause DM1 pathology through alterations of several RNA-
binding proteins including CUGBP1 and MBNL1. The phase I/II clinical trial, testing the degradation of the
mutant DMPK mRNA by antisense oligonucleotide (AON) has been recently completed. Unfortunately, it was
found that further modifications of AONs are required to improve their penetrance to skeletal muscle.
Therefore, there is an urgent need for development of alternative therapeutic approaches based on small
molecules. My lab is working with the development of a novel therapeutic approach for the treatment of CDM1
and DM1 which is based on the correction of RNA processing (including splicing) that is mis-regulated by CUG
n-GSK3β-CUGBP1 axis. We found that the activity of CUGBP1 is regulated by GSK3β-cyclin D3-CDK4
pathway and that the mutant CUG repeats alter CUGBP1 activity by the pathological increase of GSK3β
kinase. The inhibitors of GSK3 significantly reduce DM1 muscle pathology in a mouse model of DM1 (HSA
mice) and improve growth and neuromotor activity in CDM1 mouse model (DMSXL mice). These basic findings
created a strong background for the first, the GSK3-based clinical study for adult patients with CDM1. The
Phase IIa of this trial with the inhibitor of GSK3 tideglusib (TG) was recently completed by a biopharmaceutical
company AMO Pharma with encouraging results. Although the trial is in transition to the Phase II/III in pediatric
CDM1, much more mechanistic studies, including molecular analysis of the GSK3β-CUGBP1 pathway in
human patients’ materials, are needed to further support the clinical trial using TG. My application will examine
the GSK3β-CUGBP1 pathway in muscle biopsies, myofibrobasts and blood samples from DM1 and CDM1
patients with variable disease severity (Aim 1). We will also study if GSK3β was corrected in CDM1 patients
treated with TG. We will determine if the treatments with TG recover MBNL1 activity correcting global splicing
abnormalities in DM1 (Aim 2). All pathways affected by TG treatments will be defined. One more critical issue
will be addressed in my application. We recently found that the TG-treatments of DM1 myoblasts and
fibroblasts derived from patients with 200-400 CTG repeats reduce the levels of the mutant DMPK mRNA. We
propose to examine if TG improves degradation of the mutant DMPK regardless of the length of CTG
expansions (Aim 3). If TG improves the degradation of the mutant DMPK mRNA in DM1 and CDM1 myoblasts
and fibroblasts with long expansions, the inhibitors of GSK3 will represent small molecules targeting the prime
cause of CDM1 and DM1. The obtained knowledge will be critical for the further development of clinical trials of
CDM1 and DM1 that are based on the correction of GSK3β.
强直性肌营养不良1型(DM 1)是一种复杂的神经肌肉疾病,由CTG扩张引起
在染色体19 q上DMPK基因的3' UTR中重复。最长的CTG扩张影响婴儿
导致先天性DM 1(CDM 1)。CTG重复序列通过几种RNA的改变引起DM 1病理学改变,
结合蛋白包括CUGBP 1和MBNL 1。I/II期临床试验,测试
通过反义寡核苷酸(AON)突变DMPK mRNA最近已经完成。不幸的是,
发现AON需要进一步修饰以提高其对骨骼肌的亲和力。
因此,迫切需要开发基于小分子的替代治疗方法。
分子。我的实验室正在开发一种新的治疗方法来治疗CDM 1
和DM 1,其基于由CUG错误调节的RNA加工(包括剪接)的校正
n-GSK 3 β-CUGBP 1轴。我们发现CUGBP 1的活性受GSK 3 β-cyclin D3-CDK 4的调节
突变的CUG重复序列通过病理性的GSK 3 β增加而改变CUGBP 1的活性
激酶。在DM 1(HSA)小鼠模型中,GSK 3抑制剂显著减轻DM 1肌肉病理
小鼠)中的生长和神经运动活性,并改善CDM 1小鼠模型(DMSXL小鼠)中的生长和神经运动活性。这些基本发现
为第一项针对成人CDM 1患者的基于GSK 3的临床研究创造了强有力的背景。的
最近,一家生物制药公司完成了这项使用GSK 3抑制剂tideglusib(TG)的IIa期试验。
AMO Pharma取得了令人鼓舞的成绩。尽管该试验正在过渡到儿科II/III期
CDM 1,更多的机制研究,包括GSK 3 β-CUGBP 1途径的分子分析,
人类患者的材料,需要进一步支持使用TG的临床试验。我的申请将审查
来自DM 1和CDM 1的肌肉活检、肌成纤维细胞和血液样品中的GSK 3 β-CUGBP 1通路
不同疾病严重程度的患者(目标1)。我们还将研究在CDM 1患者中是否纠正了GSK 3 β
用TG治疗。我们将确定用TG治疗是否恢复MBNL 1活性,纠正整体剪接
DM 1异常(目标2)。将定义受TG治疗影响的所有途径。还有一个关键问题
会在我的申请中提及我们最近发现,TG处理的DM 1成肌细胞和
来自具有200-400个CTG重复的患者的成纤维细胞降低了突变体DMPK mRNA的水平。我们
建议检查TG是否改善突变体DMPK的降解,而不管CTG的长度如何
扩展(目标3)。如果TG促进DM 1和CDM 1成肌细胞中突变型DMPK mRNA的降解,
和具有长扩增的成纤维细胞,GSK 3的抑制剂将代表靶向引发的小分子。
CDM 1和DM 1的原因。所获得的知识将是关键的进一步发展的临床试验
CDM 1和DM 1基于GSK 3 β的校正。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.
强直性肌营养不良 1 中糖原合酶激酶 3β 的校正减少了突变 RNA 并提高了 DMSXL 小鼠的产后存活率。
- DOI:10.1128/mcb.00155-19
- 发表时间:2019
- 期刊:
- 影响因子:5.3
- 作者:Wang,Mei;Weng,Wen-Chin;Stock,Lauren;Lindquist,Diana;Martinez,Ana;Gourdon,Genevieve;Timchenko,Nikolai;Snape,Mike;Timchenko,Lubov
- 通讯作者:Timchenko,Lubov
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LUBOV T TIMCHENKO其他文献
LUBOV T TIMCHENKO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LUBOV T TIMCHENKO', 18)}}的其他基金
CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
先天性 DM1 中的中枢神经系统:发病机制和治疗机会
- 批准号:
10089488 - 财政年份:2020
- 资助金额:
$ 20.2万 - 项目类别:
CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
先天性 DM1 中的中枢神经系统:发病机制和治疗机会
- 批准号:
10553142 - 财政年份:2020
- 资助金额:
$ 20.2万 - 项目类别:
GSK3 beta study in patients with Myotonic Dystrophy 1
强直性肌营养不良患者的 GSK3 beta 研究 1
- 批准号:
10326843 - 财政年份:2019
- 资助金额:
$ 20.2万 - 项目类别:
GSK3 beta study in patients with Myotonic Dystrophy 1
强直性肌营养不良患者的 GSK3 beta 研究 1
- 批准号:
10087889 - 财政年份:2019
- 资助金额:
$ 20.2万 - 项目类别:
Inhibition of GSK3 beta as potential therapy for DM1
抑制 GSK3 beta 作为 DM1 的潜在疗法
- 批准号:
8930071 - 财政年份:2014
- 资助金额:
$ 20.2万 - 项目类别:
Inhibition of GSK3 beta as potential therapy for DM1
抑制 GSK3 beta 作为 DM1 的潜在疗法
- 批准号:
8635126 - 财政年份:2014
- 资助金额:
$ 20.2万 - 项目类别:
The toxicity of the RNA CGG repeats in FXTAS
FXTAS 中 RNA CGG 重复序列的毒性
- 批准号:
8897690 - 财政年份:2012
- 资助金额:
$ 20.2万 - 项目类别:
The toxicity of the RNA CGG repeats in FXTAS
FXTAS 中 RNA CGG 重复序列的毒性
- 批准号:
8442154 - 财政年份:2012
- 资助金额:
$ 20.2万 - 项目类别:
The toxicity of the RNA CGG repeats in FXTAS
FXTAS 中 RNA CGG 重复序列的毒性
- 批准号:
8536413 - 财政年份:2012
- 资助金额:
$ 20.2万 - 项目类别:
Mechanisms of decay of toxic CUGn RNA in DM1 patients
DM1 患者中有毒 CUGn RNA 的衰减机制
- 批准号:
7620081 - 财政年份:2008
- 资助金额:
$ 20.2万 - 项目类别:
相似国自然基金
3'-甲氧基葛根素生物合成途径中关键甲基转移酶基因的克隆与功能分析
- 批准号:31300258
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
- 批准号:81300507
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
3'-UTR单核苷酸多态性影响CYP8B1基因表达致胆囊胆固醇结石形成的机制研究
- 批准号:81370561
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
异源杂交多倍化鲫鲤特有性状的转录组及后转录组水平变化规律研究
- 批准号:31360514
- 批准年份:2013
- 资助金额:54.0 万元
- 项目类别:地区科学基金项目
HIF基因3'UTR区SNP参与胰腺癌HIF-1α表达调控的分子机制及功能研究
- 批准号:81302082
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
鼻咽癌转移相关通路分子的microRNA调控机制及3'UTR区可变剪切的作用研究
- 批准号:81372886
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
小鼠精原干细胞中APA位点研究及3'UTR使用频率数据库构建
- 批准号:31301085
- 批准年份:2013
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目